NDC properties for NDC 9 72606-022
NDC item 72606002201
| NDC 9 | 72606-022 |
|---|---|
| NDC 10 | 72606-022-01 |
| NDC Item | 72606002201 |
| packaging | 1 SYRINGE in 1 CARTON (72606-022-01) / .4 mL in 1 SYRINGE |
| BLA | BLA761219 |
| FDA SPL set id | 753287 |
| Labeler | CELLTRION USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2023-11-30 |
| Marketing status | ACTIVE |
NDC item 72606002202
| NDC 9 | 72606-022 |
|---|---|
| NDC 10 | 72606-022-02 |
| NDC Item | 72606002202 |
| packaging | 2 SYRINGE in 1 CARTON (72606-022-02) / .4 mL in 1 SYRINGE |
| BLA | BLA761219 |
| FDA SPL set id | 753287 |
| Labeler | CELLTRION USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2023-11-30 |
| Marketing status | ACTIVE |
NDC item 72606002203
| NDC 9 | 72606-022 |
|---|---|
| NDC 10 | 72606-022-03 |
| NDC Item | 72606002203 |
| packaging | 4 SYRINGE in 1 CARTON (72606-022-03) / .4 mL in 1 SYRINGE |
| BLA | BLA761219 |
| FDA SPL set id | 753287 |
| Labeler | CELLTRION USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2023-11-30 |
| Marketing status | ACTIVE |
NDC item 72606002204
| NDC 9 | 72606-022 |
|---|---|
| NDC 10 | 72606-022-04 |
| NDC Item | 72606002204 |
| packaging | 6 SYRINGE in 1 CARTON (72606-022-04) / .4 mL in 1 SYRINGE |
| BLA | BLA761219 |
| FDA SPL set id | 753287 |
| Labeler | CELLTRION USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2023-11-30 |
| Marketing status | ACTIVE |
NDC item 72606002205
| NDC 9 | 72606-022 |
|---|---|
| NDC 10 | 72606-022-05 |
| NDC Item | 72606002205 |
| packaging | 1 SYRINGE in 1 CARTON (72606-022-05) / .4 mL in 1 SYRINGE |
| BLA | BLA761219 |
| FDA SPL set id | 753287 |
| Labeler | CELLTRION USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2023-11-30 |
| Marketing status | ACTIVE |
NDC item 72606002206
| NDC 9 | 72606-022 |
|---|---|
| NDC 10 | 72606-022-06 |
| NDC Item | 72606002206 |
| packaging | 2 SYRINGE in 1 CARTON (72606-022-06) / .4 mL in 1 SYRINGE |
| BLA | BLA761219 |
| FDA SPL set id | 753287 |
| Labeler | CELLTRION USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2023-11-30 |
| Marketing status | ACTIVE |
NDC item 72606002207
| NDC 9 | 72606-022 |
|---|---|
| NDC 10 | 72606-022-07 |
| NDC Item | 72606002207 |
| packaging | 4 SYRINGE in 1 CARTON (72606-022-07) / .4 mL in 1 SYRINGE |
| BLA | BLA761219 |
| FDA SPL set id | 753287 |
| Labeler | CELLTRION USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2023-11-30 |
| Marketing status | ACTIVE |
NDC item 72606002208
| NDC 9 | 72606-022 |
|---|---|
| NDC 10 | 72606-022-08 |
| NDC Item | 72606002208 |
| packaging | 6 SYRINGE in 1 CARTON (72606-022-08) / .4 mL in 1 SYRINGE |
| BLA | BLA761219 |
| FDA SPL set id | 753287 |
| Labeler | CELLTRION USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2023-11-30 |
| Marketing status | ACTIVE |